Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
85 hedge funds and large institutions have $95.6M invested in Chinook Therapeutics, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 32 increasing their positions, 23 reducing their positions, and 18 closing their positions.
3,200% more call options, than puts
Call options by funds: $99K | Put options by funds: $3K
39% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 23
2% less funds holding
Funds holding: 87 → 85 (-2)
11% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 18
66% less capital invested
Capital invested by funds: $284M → $95.6M (-$189M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$14.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$2.84M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$2.33M |
| 4 |
AG
Artal Group
Luxembourg
|
+$1.8M |
| 5 |
Two Sigma Investments
New York
|
+$1.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$19.8M |
| 2 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$15.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.03M |
| 5 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
-$2.24M |
KDNY Hedge Fund Activity: Q4 2018 in Review
85 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q4 2018, worth a combined $95.6M — down 66% from $284M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of KDNY and 16 opened new positions — a net loss of 2 holders — while 23 trimmed existing stakes and 32 added.
The largest buyer was First Light Asset Management, opening a new position worth an estimated $14.3M. The largest seller was Wellington Management Group, cutting an estimated $19.8M.
- 85 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q4 2018, down from 87 in Q3 2018.
- Funds reported $95.6M of Chinook Therapeutics, Inc. Common Stock stock for Q4 2018, down 66% quarter-over-quarter.
- 16 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q4 2018 and 18 closed out, a net change of -2 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q4 2018 was First Light Asset Management, an estimated $14.3M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q4 2018 was Wellington Management Group, an estimated $19.8M sold.
Based on aggregated 13F filings for Q4 2018.